

1 Community occurrence of metapneumovirus, influenza A, and respiratory syncytial virus (RSV)
2 inferred from wastewater solids during the winter 2022-2023 tripledemic

3

4 **Authors**

5 Alexandria B. Boehm^{1*}, Marlene K. Wolfe², Bradley White³, Bridgette Hughes³, Dorothea Duong³,
6 Amanda Bidwell¹

7

8

9 **Affiliations**

10 1. Department of Civil & Environmental Engineering, School of Engineering and Doerr School of
11 Sustainability, Stanford University, Stanford, CA, USA

12 2. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
13 University, Atlanta, GA, USA

14 3. Verily Life Sciences, South San Francisco, CA, USA

15

16

17

18 *corresponding author: Alexandria Boehm (aboehm@stanford.edu)

19

20

21

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Abstract

Wastewater monitoring can provide insights into respiratory disease occurrence in communities that contribute to the wastewater system. Using daily measurements of RNA of influenza A (IAV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV), as well as SARS-CoV-2 in wastewater solids from eight publicly owned treatment works in the Greater San Francisco Bay Area of California between July 2022 until early May 2023, we identify a “triple-demic” when concentrations of IAV, RSV, and SARS-CoV-2 peaked at approximately the same time. HMPV was also widely circulating. We designed novel hydrolysis probe RT-PCR assays for different IAV subtype makers to discern that the dominant circulating IAV subtype was H3N2. We show that wastewater data can be used to identify onset and offset of wastewater disease occurrence events that can provide insight into disease epidemiology and timely, localized information to inform hospital staffing and clinical decision making to respond to circulating viruses. Whereas RSV and IAV wastewater events were mostly regionally coherent, HMPV events displayed localized occurrence patterns.

40 Introduction

41
42 Acute respiratory illness (ARI) accounts for a large burden of infectious disease^{1,2}; and is a
43 leading cause of death for children under 5 globally³. ARI surveillance in the United States
44 (US), and much of the world, is passive, relying on institutions to identify specific diseases
45 through clinical specimens and regularly reporting results to a government agency. As a result,
46 ARI surveillance is biased towards identifying infections in individuals with co-morbidities and/or
47 where symptoms are severe⁴. Resultant lack of knowledge on occurrence and trends in
48 circulating respiratory disease dynamics limits institutional awareness to guide public health
49 response and clinical decision making. Additionally, the lack of robust, unbiased data on
50 disease occurrence limits efforts to understand disease epidemiology.

51
52 During the COVID-19 pandemic, the circulation of respiratory viruses changed dramatically
53 according to both clinical surveillance^{5,6} and wastewater monitoring⁷. For example, in the US,
54 there was limited influenza or RSV circulation in the northern hemisphere winter of 2021-
55 2022^{5,8}. During winter 2022-2023, the US experienced a “triple-demic” of respiratory viruses as
56 clinics and hospitals recorded large numbers SARS-CoV-2, influenza, and RSV infections, at
57 times overwhelming hospital capacity particularly in pediatric units⁹. Nearly 40% of United
58 States households reported being infected by SARS-CoV-2, influenza, or RSV during the
59 triple-demic period¹⁰.

60
61 In the present study, we explore the potential for wastewater monitoring, also referred to as
62 wastewater-base epidemiology, to inform the onset and progression of important respiratory
63 viruses during this triple-demic period in the United States. We measured concentrations of
64 genomic nucleic-acids of influenza A (IAV), RSV, SARS-CoV-2, as well as human
65 metapneumovirus (HMPV) in wastewater solids daily in eight publicly owned treatment works

66 (POTWs) in the Greater San Francisco Bay Area of California, USA during winter 2022-2023.
67 We find that the unusual co-occurrence of the onset of these outbreaks is identifiable using
68 wastewater monitoring, and moreover HMPV was also circulating. Whereas clinical testing data
69 are affected by an individual's test seeking behavior and test availability¹¹⁻¹³, as well as
70 institutional reporting delays which can be weeks in duration^{14,15}, wastewater data are available
71 within 24 hours of sample collection and provide information about the entire community
72 contributing to the wastewater system. We posit that wastewater can be used to help identify
73 the onset and offset of respiratory virus transmission events, as well as the peak of such events.
74 This in turn can inform clinical decision making as well as institutional public health messaging
75 and individual behaviors.

76

77 **Methods**

78

79 **Sample collection.** Eight POTWs located in the greater San Francisco Bay Area (extending to
80 Sacramento) in California, USA contributed daily samples of wastewater settled solids for the
81 prospective study (Figure S1, additional POTW details are in Wolfe et al.¹⁶). Approximately
82 50 ml of settled solids were collected daily between 7/1/22 (month/day/year format) and 5/7/23.
83 Additional details of sample collection are in the SI. Samples were immediately stored at 4°C
84 and transported to the laboratory where processing began within 6 h of collection. 2472 samples
85 were collected.

86

87 **Sample preparation and RNA extraction.** Details of sample preparation and nucleic-acid
88 extraction have been described in detail elsewhere^{7,16-18} and are described briefly in the SI.
89 RNA was extracted from 10 replicate aliquots per sample and then subjected to an inhibitor
90 removal step. Extraction-negative controls (water) and extraction-positive controls were
91 extracted using the same protocol as the homogenized samples. The positive controls consisted

92 of SARS-CoV-2 genomic RNA (ATCC VR-1986D), Twist Synthetic Influenza A H3N2 RNA
93 Control (Twist 103002), Intact RSV B virus (Zepto NATFVP-NNS), and a gene block (double-
94 stranded DNA [dsDNA] purchased from IDT) for the HMPV target in the BCoV-spiked DNA/RNA
95 shield solution described above.

96
97 **Droplet digital PCR.** RNA extracts were used as template in digital droplet RT-PCR assays for
98 PMMoV, BCoV, SARS-CoV-2 N, IAV M, RSV N, and HMPV L gene targets in multiplex assays
99 which have been previously published^{7,19}. Each of the 10 replicate nucleic-acid extracts were
100 run in their own well. Assays were multiplexed using the probe mixing approach (see SI and
101 Table S1). PMMoV is highly abundant in wastewater globally²⁰ and is used here as an internal
102 recovery and fecal strength control²¹. Undiluted extract was used for the human viral assay
103 template, and a 1:100 dilution of the extract was used for the BCoV/PMMoV assay template.
104 Details of the digital RT-PCR have been published and are included in the SI.

105
106 Concentrations of RNA targets were converted to concentrations per dry weight of solids in units
107 of cp/g using dimensional analysis. The total error is reported as standard deviations and
108 includes the errors associated with the Poisson distribution and the variability among the 10
109 replicates. BCoV recovery was determined by normalizing the BCoV concentration by the
110 expected concentration given the value measured in the spiked DNA/RNA shield. BCoV
111 recovery was used as a process control and not used in the calculation of concentrations;
112 samples were rerun in cases where the recovery of BCoV was less than 1%.

113
114 **Influenza subtypes.** We designed and tested novel RT-PCR primers and internal hydrolysis
115 probes targeting the H1 subtype of the hemagglutinin (HA) gene, H3 subtype of the HA gene,
116 N1 subtype of the neuraminidase (NA) gene, and N2 subtype of the NA gene of IAV. Primers

117 and probes were then screened for specificity in silico, and in vitro against other respiratory and
118 enteric viruses (see SI, Table S2).

119
120 We retrospectively tested two samples per week between 7/1/22 and 3/31/23 (covering most of
121 the IAV wastewater event) from SJ POTW for the four influenza A subtype markers (N1, N2, H1,
122 H3). We also re-analyzed the samples to quantify the IAV M gene in order to report the ratio of
123 the subtype markers to M gene (see SI).

124
125 **Clinical data.** We used state-aggregated weekly clinical sample positivity rates from sentinel
126 laboratories for IAV, RSV and HMPV. IAV, RSV, and a fraction of the HMPV data are publicly
127 available²², the remaining HMPV data were provided by California Department of Public Health
128 (CDPH). State-aggregated daily positivity rates for COVID-19 are publicly available
129 (<https://data.chhs.ca.gov/dataset/covid-19-time-series-metrics-by-county-and-state>).

130
131 **Data analysis.** Human viral RNA concentrations were normalized by PMMoV RNA; 5-d trimmed
132 averages were used to visualize data and identify the date of their peak maximum
133 concentrations. The onset dates of IAV, RSV, and HMPV wastewater events were identified as
134 the first day for which all samples in a 14-d look back period had concentration higher than 2000
135 copies/g., which is approximately twice the lowest detectable concentration. The offset dates of
136 IAV, RSV, and HMPV wastewater events were identified as the first day after an onset event for
137 which only 7 samples during a 14-d look back period had concentrations over 2000 copies/g.

138
139 We tested whether PMMoV-normalized viral RNA concentrations at each POTW were
140 correlated to the same measurements at the other eight POTWs ($28*4 = 112$ hypothesis tests),
141 and whether PMMoV-normalized viral RNA concentrations were correlated within POTWs (48
142 tests) using Kendall's tau as these data tend to not be normally distributed. We also tested the

143 hypothesis that PMMoV-normalized viral RNA correlated to state-aggregated positivity rates (32
144 tests). Since IAV, RSV, and HMPV positivity rates are aggregated weekly, we used weekly
145 median PMMoV-normalized viral RNA concentrations to test the hypothesis. We used a p value
146 of 0.00026 (0.05/192) which corresponds to $\alpha = 0.05$ with a Bonferroni correction. Results
147 were similar when analyses were carried out with variables that were not PMMoV-normalized.

148
149 This study was reviewed by the State of California Health and Human Services Agency
150 Committee for the Protection of Human Subjects and determined to be Exempt from oversight.
151 Wastewater data are publicly available (<https://purl.stanford.edu/gp563rt4747>). Data collected
152 between 7/1/22 and 12/31/22 are publicly available through a Data Descriptor²³.

153

154 **Results**

155

156 **QA/QC.** Results are reported as suggested in the Environmental Microbiology Minimal
157 Information guidelines²⁴ (Figure S2). Extraction and PCR negative and positive controls
158 performed as expected (negative and positive, respectively). Median BCoV recovery in these
159 solids samples was 1.2 (interquartile range = 0.92-1.72, n=2472); values greater than 1 are
160 likely a result of uncertainty in quantifying the amount of BCoV spiked in the DNA/RNA shield.

161

162 **Novel IAV subtype assay sensitivity and specificity.** In silico analysis indicated no cross
163 reactivity of the novel RT-PCR probe-based assays (Table S3) with sequences deposited in
164 NCBI. The novel assays for IAV N1, N2, H1 and H3 were tested in vitro against non-target viral
165 gRNA as well as target gRNA. No cross reactivity was observed.

166

167 **Viral RNA in wastewater solids.** Viral concentrations were dynamic over the project duration,
168 with most showing elevated concentrations in the winter (Figure 1). PMMoV-normalized HMPV,

169 IAV, RSV, and SARS-CoV-2 RNA concentrations were each positively and significantly
170 associated between the eight POTWs, respectively (IAV tau: 0.49 to 0.64, RSV tau: 0.53 to
171 0.71, HMPV tau: 0.37 to 0.56, SARS-CoV-2 tau: 0.27 to 0.45, all $p < 10^{-12}$, Figure S3) suggesting
172 coarse temporal coherence across the region.

173
174 Within each POTW, PMMoV-normalized IAV, RSV, HMPV, and SARS-CoV-2 RNA
175 concentrations were generally positively associated with each other suggesting coherence
176 within a POTW (tau: 0.15 to 0.56, all $p < 0.00026$, depending on POTW and specific
177 measurements, Figure S4). The exceptions are at PA where HMPV was not associated with
178 IAV, at Gil where HMPV was not associated with SARS-CoV-2, and at SAC and Ocean, where
179 HMPV was not significantly associated with IAV or SARS-CoV-2. Taus were generally highest
180 between IAV and RSV, and slowest between HMPV and both IAV and SARS-CoV-2.

181
182 State-aggregated clinical specimen positivity rates for IAV, RSV, HMPV, and SARS-CoV-2
183 show peaks in winter months (Figure S5). Weekly median PMMoV-normalized concentrations of
184 all viruses were significantly, positively correlated with the associated clinical positivity rate (see
185 SI, all $p < 10^{-6}$).

186
187 The peak wastewater concentrations varied across POTWs for the different viral targets (Table
188 1). Peak RSV occurred between 11/25/22 and 12/14/22, peak IAV occurred between 26 Nov
189 and 13 Dec, and peak HMPV occurred between 11/26/22 and 3/30/23, depending on POTW.
190 For context, peak SARS-CoV-2 occurred between 11/30/22 and 3/16/23.

191
192 We identified dates of wastewater event onsets and offsets for RSV, IAV, and HMPV, but not for
193 SARS-CoV-2 as its levels were such that the entire period of the study would be defined as a
194 wastewater event (Table 1). We observed wintertime RSV wastewater events at all 8 POTWs

195 with onsets between 9/17/22 and 10/24/22, and offsets between 3/20/23 and 4/29/23,
196 depending on POTW. The period of time between onset and offset varied between 147 and 215
197 days (median = 190 days).

198
199 We observed a summer IAV wastewater event at two POTWs (SJ and PA); both onset on
200 7/14/22 and offset on 7/23/22 (SJ) and 9/21/22 (PA). We observed wintertime wastewater
201 events at all 8 POTWs with onsets between 10/26/22 and 11/18/22 and offsets between 1/25/23
202 and 3/3/23. The duration of the wintertime events ranged from 73 and 122 days (median = 104
203 days). IAV subtype analysis at SJ did not detect N1, but detected N2, H1, and H3. When
204 detected, the ratio of N2/IAV ranged from 0.3 to over 1 (median = 0.6), H1/IAV ranged from from
205 0.03 to 0.35 (median = 0.07), and H3/IAV ranged from from 0.1 to 0.4 (median = 0.2) (Figure
206 S6).

207
208 We observed a fall HMPV wastewater event at one POTW (SE) with onset on 9/1/22 and offset
209 on 9/24/22. We observed wintertime HMPV wastewater events for all 8 POTWs with onsets
210 between 8/6/22 and 12/3/22. Data from the 8 POTWs indicated on 5/7/23, the end of the study,
211 that none of the HMPV events had offset suggesting minimal durations (assuming offset
212 occurred on 5/8, the day after the study ended) between 156 and 275 days (median = 187
213 days).

214
215 **Discussion**

216
217 Influenza A, RSV, and SARS-CoV-2 RNA in wastewater solids in the Greater San Francisco
218 Bay Area of California are reflective of the winter 2022-2023 “triple-demic” when cases of
219 influenza, RSV, and COVID-19 increased dramatically with similar onset periods, sometimes
220 overwhelming hospital capacity⁹. Wastewater monitoring of human metapneumovirus (HMPV)

221 RNA suggests HMPV was also circulating in communities during the tripledemic, but with
222 slightly different outbreak timing and continued activity after IAV and RSV offset in most areas.
223 HMPV was discovered in 2001²⁵ and clinical presentation can be indistinguishable from
224 influenza and RSV²⁶. Hospitalization rates associated with HMPV for children are similar to
225 those for influenza²⁷. Although there are vaccines available for IAV²⁸ and the first vaccine was
226 approved by the FDA for RSV in 2023 (although only for adults age > 60 yo)^{29,30}, there is no
227 HMPV vaccine currently available³¹. IAV subtype analysis suggested that H3N2 was more
228 common than H1N1, consistent with subtyping of clinical samples²².

229
230 Wastewater data was able to resolve information on occurrence patterns at higher resolution
231 than clinical data, showing differences in occurrence patterns of IAV, RSV, SARS-CoV-2, and
232 HMPV community infections. For IAV, we identified two localized summertime events at two
233 POTWs located 15 km apart in Santa Clara County and a late localized fall HMPV event was
234 identified at one POTW located in San Francisco County, neither of which were reflected in their
235 respective state-aggregated positivity rate data.

236
237 Wintertime wastewater events were evident for IAV, RSV, and HMPV, but their characteristics
238 differed. IAV events were temporally coherent throughout the region with onsets, peaks, and
239 offsets occurring at all POTWs within the same three, three, and five week windows,
240 respectively. RSV events were also regionally temporally coherent; all POTWs had onsets,
241 peaks, and offsets within the same five, three, and five week windows, respectively. However,
242 wintertime RSV onset and offsets occurred one month earlier and later, respectively, than those
243 of IAV across all POTWs, a pattern also discernible in the state-aggregated clinical data. RSV
244 peak concentrations occurred at the same time as peak IAV concentrations. SARS-CoV-2
245 concentrations also had local peaks at the same time as RSV and IAV suggesting community

246 infections reach their height in unison, consistent with reports of the triple endemic overwhelming
247 some hospital capacities⁹.

248
249 HMPV wastewater events differed widely in the timing of onset and peak among the eight
250 POTWs, suggesting localized dynamics; onsets dates varied by up to 4 months and the timing
251 of the peak varied by up to 5 months. Localized HMPV dynamics is further supported by the
252 relatively weak correlations between HMPV concentrations and concentrations of the other
253 viruses that showed patterns of regional coherence. Although HMPV concentrations were
254 positively associated with the state-aggregated positivity rate data, there are clearly localized
255 dynamics in the wastewater events that are not reflected in the state-aggregated clinical data.
256 More localized data on HMPV circulation is not available as testing is extremely limited⁷.

257 Previous studies of clinical HMPV infections suggest variable seasonal infection from year-to-
258 year in contrast to typical patterns in seasonal RSV and IAV infections²⁷.

259
260 A global systematic review³² indicates that seasonal IAV, RSV, and HMPV epidemics typically
261 overlap. RSV epidemics typically start earlier than IAV epidemics by 0.3 months in temperate
262 regions³². In our study RSV wastewater events onset 1.2 months (median) before IAV. The
263 same review indicates IAV and RSV epidemics in temperate areas are 3.8 and 4.6 months in
264 duration, respectively. Wastewater events for IAV and RSV were 3.5 and 4.8 months in duration
265 (medians). Temperate HMPV epidemics began 1.7 months after RSV and were 4.8 months in
266 duration. In the present study, HMPV wastewater events began 1 month after RSV (median),
267 and were at least 6.3 months in duration.

268
269 While the clinical test positivity data used here provides insight into disease circulation during
270 the study time period, there is no data on community incidence or prevalence of IAV, RSV, or
271 HMPV in the study area. Additionally, data on COVID-19 incidence and prevalence degraded

272 during this time period owing to the wide availability of at home rapid tests^{12,33}, the results of
273 which are not reportable to public health agencies in our study area. IAV, RSV, HMPV, and
274 COVID-19 test positivity rates serve as proxies for trends in disease occurrence, but it is
275 important to acknowledge that the rates reflect those of severely symptomatic cases. There is
276 also a significant delay in those data being available, usually with results available and updated
277 2-4 weeks after specimen collection. Wastewater represents composite biological samples from
278 an entire community including those who are asymptomatic or mildly symptomatic. Wastewater
279 therefore complements data on clinical test positivity. Given the delays associated with the
280 positivity rate data, and the sparseness of localized positivity rate data, wastewater can serve as
281 an indicator of the first onsets of localized, community infections. While spatial and temporal
282 coherence was observed for IAV and RSV events, HMPV showed more localized dynamics.
283 This has been shown previously for other diseases; localized dynamics of mpox were also
284 evident from wastewater monitoring³⁴. We explored other methods of identifying wastewater
285 events including using different concentration thresholds and look-back periods. All gave similar
286 relative results among the viruses; a public health organization could decide on data analysis
287 methods for identifying wastewater events that were fit for their purposes.

288

289 **Supporting Information.** Additional methodological details as well as Tables S1-S3, and
290 Figures S1-S6.

291

292 **Acknowledgements.** We acknowledge the numerous people who contributed to wastewater
293 sample collection and Allegra Koch for her support with the literature review. This research was
294 performed on the ancestral and unceded lands of the Muwekma Ohlone people. We pay our
295 respects to them and their Elders, past and present, and are grateful for the opportunity to live
296 and work here.

297

298

299

300 **References**

301

- 302 (1) Jin, X.; Ren, J.; Li, R.; Gao, Y.; Zhang, H.; Li, J.; Zhang, J.; Wang, X.; Wang, G. Global
303 Burden of Upper Respiratory Infections in 204 Countries and Territories, from 1990 to
304 2019. *eClinicalMedicine* **2021**, *37*. <https://doi.org/10.1016/j.eclinm.2021.100986>.
- 305 (2) Vos, T.; Lim, S. S.; Abbafati, C.; Abbas, K. M.; Abbasi, M.; Abbasifard, M.; Abbasi-
306 Kangevari, M.; Abbastabar, H.; Abd-Allah, F.; Abdelalim, A.; Abdollahi, M.; Abdollahpour,
307 I.; Abolhassani, H.; Aboyans, V.; Abrams, E. M.; Abreu, L. G.; Abrigo, M. R. M.; Abu-
308 Raddad, L. J.; Abushouk, A. I.; Acebedo, A.; Ackerman, I. N.; Adabi, M.; Adamu, A. A.;
309 Adebayo, O. M.; Adekanmbi, V.; Adelson, J. D.; Adetokunboh, O. O.; Adham, D.; Afshari,
310 M.; Afshin, A.; Agardh, E. E.; Agarwal, G.; Agesa, K. M.; Aghaali, M.; Aghamir, S. M. K.;
311 Agrawal, A.; Ahmad, T.; Ahmadi, A.; Ahmadi, M.; Ahmadi, H.; Ahmadpour, E.; Akalu, T.
312 Y.; Akinyemi, R. O.; Akinyemiju, T.; Akombi, B.; Al-Aly, Z.; Alam, K.; Alam, N.; Alam, S.;
313 Alam, T.; Alanzi, T. M.; Albertson, S. B.; Alcalde-Rabanal, J. E.; Alema, N. M.; Ali, M.; Ali,
314 S.; Alicandro, G.; Aljanzadeh, M.; Alinia, C.; Alipour, V.; Aljunid, S. M.; Alla, F.; Allebeck,
315 P.; Almasi-Hashiani, A.; Alonso, J.; Al-Raddadi, R. M.; Altirkawi, K. A.; Alvis-Guzman, N.;
316 Alvis-Zakzuk, N. J.; Amini, S.; Amini-Rarani, M.; Aminorroaya, A.; Amiri, F.; Amit, A. M. L.;
317 Amugsi, D. A.; Amul, G. G. H.; Anderlini, D.; Andrei, C. L.; Andrei, T.; Anjomshoa, M.;
318 Ansari, F.; Ansari, I.; Ansari-Moghaddam, A.; Antonio, C. A. T.; Antony, C. M.;
319 Antriyandarti, E.; Anvari, D.; Anwer, R.; Arabloo, J.; Arab-Zozani, M.; Aravkin, A. Y.; Ariani,
320 F.; Ärnlöv, J.; Aryal, K. K.; Arzani, A.; Asadi-Aliabadi, M.; Asadi-Pooya, A. A.; Asghari, B.;
321 Ashbaugh, C.; Atnafu, D. D.; Atre, S. R.; Ausloos, F.; Ausloos, M.; Ayala Quintanilla, B. P.;
322 Ayano, G.; Ayanore, M. A.; Aynalem, Y. A.; Azari, S.; Azarian, G.; Azene, Z. N.; Babae,
323 E.; Badawi, A.; Bagherzadeh, M.; Bakhshaei, M. H.; Bakhtiari, A.; Balakrishnan, S.; Balalla,
324 S.; Balassyano, S.; Banach, M.; Banik, P. C.; Bannick, M. S.; Bante, A. B.; Baraki, A. G.;
325 Barboza, M. A.; Barker-Collo, S. L.; Barthelemy, C. M.; Barua, L.; Barzegar, A.; Basu, S.;
326 Baune, B. T.; Bayati, M.; Bazmandegan, G.; Bedi, N.; Beghi, E.; Béjot, Y.; Bello, A. K.;
327 Bender, R. G.; Bennett, D. A.; Bennitt, F. B.; Bensenor, I. M.; Benziger, C. P.; Berhe, K.;
328 Bernabe, E.; Bertolacci, G. J.; Bhageerathy, R.; Bhala, N.; Bhandari, D.; Bhardwaj, P.;
329 Bhattacharyya, K.; Bhutta, Z. A.; Bibi, S.; Biehl, M. H.; Bikbov, B.; Bin Sayeed, M. S.;
330 Biondi, A.; Biriha, B. M.; Bisanzio, D.; Bisignano, C.; Biswas, R. K.; Bohlouli, S.; Bohluli,
331 M.; Bolla, S. R. R.; Bolor, A.; Boon-Dooley, A. S.; Borges, G.; Borzi, A. M.; Bourne, R.;
332 Brady, O. J.; Brauer, M.; Brayne, C.; Breitborde, N. J. K.; Brenner, H.; Briant, P. S.; Briggs,
333 A. M.; Briko, N. I.; Britton, G. B.; Bryazka, D.; Buchbinder, R.; Bumgarner, B. R.; Busse, R.;
334 Butt, Z. A.; Caetano dos Santos, F. L.; Cámera, L. L. A.; Campos-Nonato, I. R.; Car, J.;
335 Cárdenas, R.; Carreras, G.; Carrero, J. J.; Carvalho, F.; Castaldelli-Maia, J. M.;
336 Castañeda-Orjuela, C. A.; Castelpietra, G.; Castle, C. D.; Castro, F.; Catalá-López, F.;
337 Causey, K.; Cederroth, C. R.; Cercy, K. M.; Cerin, E.; Chandan, J. S.; Chang, A. R.;
338 Charlson, F. J.; Chattu, V. K.; Chaturvedi, S.; Chimed-Ochir, O.; Chin, K. L.; Cho, D. Y.;
339 Christensen, H.; Chu, D.-T.; Chung, M. T.; Cicuttini, F. M.; Ciobanu, L. G.; Cirillo, M.;
340 Collins, E. L.; Compton, K.; Conti, S.; Cortesi, P. A.; Costa, V. M.; Cousin, E.; Cowden, R.
341 G.; Cowie, B. C.; Cromwell, E. A.; Cross, D. H.; Crowe, C. S.; Cruz, J. A.; Cunningham, M.;
342 Dahlawi, S. M. A.; Damiani, G.; Dandona, L.; Dandona, R.; Darwesh, A. M.; Daryani, A.;
343 Das, J. K.; Das Gupta, R.; das Neves, J.; Dávila-Cervantes, C. A.; Davletov, K.; De Leo,
344 D.; Dean, F. E.; DeCleene, N. K.; Deen, A.; Degenhardt, L.; Dellavalle, R. P.; Demeke, F.
345 M.; Demsie, D. G.; Denova-Gutiérrez, E.; Dereje, N. D.; Dervenis, N.; Desai, R.; Desalew,
346 A.; Dessie, G. A.; Dharmaratne, S. D.; Dhungana, G. P.; Dianatinasab, M.; Diaz, D.; Dibaji
347 Forooshani, Z. S.; Dingels, Z. V.; Dirac, M. A.; Djalalinia, S.; Do, H. T.; Dokova, K.;

348 Dorostkar, F.; Doshi, C. P.; Doshmangir, L.; Douiri, A.; Doxey, M. C.; Driscoll, T. R.;
349 Dunachie, S. J.; Duncan, B. B.; Duraes, A. R.; Eagan, A. W.; Ebrahimi Kalan, M.;
350 Edvardsson, D.; Ehrlich, J. R.; El Nahas, N.; El Sayed, I.; El Tantawi, M.; Elbarazi, I.;
351 Elgendy, I. Y.; Elhabashy, H. R.; El-Jaafary, S. I.; Elyazar, I. R.; Emamian, M. H.; Emmons-
352 Bell, S.; Erskine, H. E.; Eshrati, B.; Eskandarieh, S.; Esmaeilnejad, S.; Esmaeilzadeh, F.;
353 Esteghamati, A.; Estep, K.; Etemadi, A.; Etisso, A. E.; Farahmand, M.; Faraj, A.; Fareed,
354 M.; Faridnia, R.; Farinha, C. S. e S.; Farioli, A.; Faro, A.; Faruque, M.; Farzadfar, F.;
355 Fattahi, N.; Fazlzadeh, M.; Feigin, V. L.; Feldman, R.; Fereshtehnejad, S.-M.; Fernandes,
356 E.; Ferrari, A. J.; Ferreira, M. L.; Filip, I.; Fischer, F.; Fisher, J. L.; Fitzgerald, R.; Flohr, C.;
357 Flor, L. S.; Foigt, N. A.; Folayan, M. O.; Force, L. M.; Fornari, C.; Foroutan, M.; Fox, J. T.;
358 Freitas, M.; Fu, W.; Fukumoto, T.; Furtado, J. M.; Gad, M. M.; Gakidou, E.; Galles, N. C.;
359 Gallus, S.; Gamkrelidze, A.; Garcia-Basteiro, A. L.; Gardner, W. M.; Geberemariam, B. S.;
360 Gebrehiwot, A. M.; Gebremedhin, K. B.; Gebreslassie, A. A. A. A.; Gershberg Hayoon, A.;
361 Gething, P. W.; Ghadimi, M.; Ghadiri, K.; Ghafourifard, M.; Ghajar, A.; Ghamari, F.;
362 Ghashghaee, A.; Ghiasvand, H.; Ghith, N.; Gholamian, A.; Gilani, S. A.; Gill, P. S.;
363 Gitimoghaddam, M.; Giussani, G.; Goli, S.; Gomez, R. S.; Gopalani, S. V.; Gorini, G.;
364 Gorman, T. M.; Gottlich, H. C.; Goudarzi, H.; Goulart, A. C.; Goulart, B. N. G.; Grada, A.;
365 Grivna, M.; Grosso, G.; Gubari, M. I. M.; Gugnani, H. C.; Guimaraes, A. L. S.; Guimarães,
366 R. A.; Guled, R. A.; Guo, G.; Guo, Y.; Gupta, R.; Haagsma, J. A.; Haddock, B.; Hafezi-
367 Nejad, N.; Hafiz, A.; Hagins, H.; Haile, L. M.; Hall, B. J.; Halvaei, I.; Hamadeh, R. R.;
368 Hamagharib Abdullah, K.; Hamilton, E. B.; Han, C.; Han, H.; Hankey, G. J.; Haro, J. M.;
369 Harvey, J. D.; Hasaballah, A. I.; Hasanzadeh, A.; Hashemian, M.; Hassanipour, S.;
370 Hassankhani, H.; Havmoeller, R. J.; Hay, R. J.; Hay, S. I.; Hayat, K.; Heidari, B.; Heidari,
371 G.; Heidari-Soureshjani, R.; Hendrie, D.; Henrikson, H. J.; Henry, N. J.; Herteliu, C.;
372 Heydarpour, F.; Hird, T. R.; Hoek, H. W.; Hole, M. K.; Holla, R.; Hoogar, P.; Hosgood, H.
373 D.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Hoy, D. G.; Hsairi, M.; Hsieh,
374 V. C.; Hu, G.; Huda, T. M.; Hugo, F. N.; Huynh, C. K.; Hwang, B.-F.; Iannucci, V. C.;
375 Ibitoye, S. E.; Ikuta, K. S.; Ilesanmi, O. S.; Ilic, I. M.; Ilic, M. D.; Inbaraj, L. R.; Ippolito, H.;
376 Irvani, S. S. N.; Islam, M. M.; Islam, M.; Islam, S. M. S.; Islami, F.; Iso, H.; Ivers, R. Q.; Iwu,
377 C. C. D.; Iyamu, I. O.; Jaafari, J.; Jacobsen, K. H.; Jadidi-Niaragh, F.; Jafari, H.; Jafarinia,
378 M.; Jahagirdar, D.; Jahani, M. A.; Jahanmehr, N.; Jakovljevic, M.; Jalali, A.; Jalilian, F.;
379 James, S. L.; Janjani, H.; Janodia, M. D.; Jayatilleke, A. U.; Jeemon, P.; Jenabi, E.; Jha, R.
380 P.; Jha, V.; Ji, J. S.; Jia, P.; John, O.; John-Akinola, Y. O.; Johnson, C. O.; Johnson, S. C.;
381 Jonas, J. B.; Joo, T.; Joshi, A.; Jozwiak, J. J.; Jürisson, M.; Kabir, A.; Kabir, Z.; Kalani, H.;
382 Kalani, R.; Kalankesh, L. R.; Kalhor, R.; Kamiab, Z.; Kanchan, T.; Karami Matin, B.; Karch,
383 A.; Karim, M. A.; Karimi, S. E.; Kassa, G. M.; Kassebaum, N. J.; Katikireddi, S. V.;
384 Kawakami, N.; Kayode, G. A.; Keddie, S. H.; Keller, C.; Kereselidze, M.; Khafaie, M. A.;
385 Khalid, N.; Khan, M.; Khatab, K.; Khater, M. M.; Khatib, M. N.; Khayamzadeh, M.;
386 Khodayari, M. T.; Khundkar, R.; Kianipour, N.; Kielsing, C.; Kim, D.; Kim, Y.-E.; Kim, Y. J.;
387 Kimokoti, R. W.; Kisa, A.; Kisa, S.; Kissimova-Skarbek, K.; Kivimäki, M.; Kneib, C. J.;
388 Knudsen, A. K. S.; Kocarnik, J. M.; Kolola, T.; Kopec, J. A.; Kosen, S.; Koul, P. A.;
389 Koyanagi, A.; Kravchenko, M. A.; Krishan, K.; Krohn, K. J.; Kuate Defo, B.; Kucuk Bicer,
390 B.; Kumar, G. A.; Kumar, M.; Kumar, P.; Kumar, V.; Kumares, G.; Kurmi, O. P.; Kusuma,
391 D.; Kyu, H. H.; La Vecchia, C.; Lacey, B.; Lal, D. K.; Laloo, R.; Lam, J. O.; Lami, F. H.;
392 Landires, I.; Lang, J. J.; Lansingh, V. C.; Larson, S. L.; Larsson, A. O.; Lasrado, S.; Lassi,
393 Z. S.; Lau, K. M.-M.; Lavados, P. M.; Lazarus, J. V.; Ledesma, J. R.; Lee, P. H.; Lee, S. W.
394 H.; LeGrand, K. E.; Leigh, J.; Leonardi, M.; Lescinsky, H.; Leung, J.; Levi, M.; Lewington,
395 S.; Li, S.; Lim, L.-L.; Lin, C.; Lin, R.-T.; Linehan, C.; Linn, S.; Liu, H.-C.; Liu, S.; Liu, Z.;
396 Looker, K. J.; Lopez, A. D.; Lopukhov, P. D.; Lorkowski, S.; Lotufo, P. A.; Lucas, T. C. D.;
397 Lugo, A.; Lunevicius, R.; Lyons, R. A.; Ma, J.; MacLachlan, J. H.; Maddison, E. R.;
398 Maddison, R.; Madotto, F.; Mahasha, P. W.; Mai, H. T.; Majeed, A.; Maled, V.; Maleki, S.;

399 Malekzadeh, R.; Malta, D. C.; Mamun, A. A.; Manafi, A.; Manafi, N.; Manguerra, H.;
400 Mansouri, B.; Mansournia, M. A.; Mantilla Herrera, A. M.; Maravilla, J. C.; Marks, A.;
401 Martins-Melo, F. R.; Martopullo, I.; Masoumi, S. Z.; Massano, J.; Massenburg, B. B.;
402 Mathur, M. R.; Maulik, P. K.; McAlinden, C.; McGrath, J. J.; McKee, M.; Mehndiratta, M.
403 M.; Mehri, F.; Mehta, K. M.; Meitei, W. B.; Memiah, P. T. N.; Mendoza, W.; Menezes, R.
404 G.; Mengesha, E. W.; Mengesha, M. B.; Mereke, A.; Meretoja, A.; Meretoja, T. J.;
405 Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Michalek, I. M.; Mihretie, K. M.; Miller, T. R.;
406 Mills, E. J.; Mirica, A.; Mirrakhimov, E. M.; Mirzaei, H.; Mirzaei, M.; Mirzaei-Alavijeh, M.;
407 Misganaw, A. T.; Mithra, P.; Moazen, B.; Moghadaszadeh, M.; Mohamadi, E.; Mohammad,
408 D. K.; Mohammad, Y.; Mohammad Gholi Mezerji, N.; Mohammadian-Hafshejani, A.;
409 Mohammadifard, N.; Mohammadpourhodki, R.; Mohammed, S.; Mokdad, A. H.; Molokhia,
410 M.; Momen, N. C.; Monasta, L.; Mondello, S.; Mooney, M. D.; Moosazadeh, M.; Moradi, G.;
411 Moradi, M.; Moradi-Lakeh, M.; Moradzadeh, R.; Moraga, P.; Morales, L.; Morawska, L.;
412 Moreno Velásquez, I.; Morgado-da-Costa, J.; Morrison, S. D.; Mosser, J. F.; Mouodi, S.;
413 Mousavi, S. M.; Mousavi Khaneghah, A.; Mueller, U. O.; Munro, S. B.; Muriithi, M. K.;
414 Musa, K. I.; Muthupandian, S.; Naderi, M.; Nagarajan, A. J.; Nagel, G.; Naghshtabrizi, B.;
415 Nair, S.; Nandi, A. K.; Nangia, V.; Nansseu, J. R.; Nayak, V. C.; Nazari, J.; Negoï, I.; Negoï,
416 R. I.; Netsere, H. B. N.; Ngunjiri, J. W.; Nguyen, C. T.; Nguyen, J.; Nguyen, M.; Nguyen,
417 M.; Nichols, E.; Nigatu, D.; Nigatu, Y. T.; Nikbakhsh, R.; Nixon, M. R.; Nnaji, C. A.;
418 Nomura, S.; Norrving, B.; Noubiap, J. J.; Nowak, C.; Nunez-Samudio, V.; Ofoïu, A.;
419 Oancea, B.; Odell, C. M.; Ogbo, F. A.; Oh, I.-H.; Okunga, E. W.; Oladnabi, M.; Olagunju, A.
420 T.; Olusanya, B. O.; Olusanya, J. O.; Oluwasanu, M. M.; Omar Bali, A.; Omer, M. O.; Ong,
421 K. L.; Onwujekwe, O. E.; Orji, A. U.; Orpana, H. M.; Ortiz, A.; Ostroff, S. M.; Otstavnov, N.;
422 Otstavnov, S. S.; Øverland, S.; Owolabi, M. O.; P A, M.; Padubidri, J. R.; Pakhare, A. P.;
423 Palladino, R.; Pana, A.; Panda-Jonas, S.; Pandey, A.; Park, E.-K.; Parmar, P. G. K.;
424 Pasupula, D. K.; Patel, S. K.; Paternina-Caicedo, A. J.; Pathak, A.; Pathak, M.; Patten, S.
425 B.; Patton, G. C.; Paudel, D.; Pazoki Toroudi, H.; Peden, A. E.; Pennini, A.; Pepito, V. C.
426 F.; Peprah, E. K.; Pereira, A.; Pereira, D. M.; Perico, N.; Pham, H. Q.; Phillips, M. R.;
427 Pigott, D. M.; Pilgrim, T.; Pilz, T. M.; Pirsaeheb, M.; Plana-Ripoll, O.; Plass, D.; Pokhrel, K.
428 N.; Polibin, R. V.; Polinder, S.; Polkinghorne, K. R.; Postma, M. J.; Pourjafar, H.;
429 Pourmalek, F.; Pourmirza Kalhori, R.; Pourshams, A.; Poznańska, A.; Prada, S. I.;
430 Prakash, V.; Pribadi, D. R. A.; Pupillo, E.; Quazi Syed, Z.; Rabiee, M.; Rabiee, N.; Radfar,
431 A.; Rafiee, A.; Rafiei, A.; Raggi, A.; Rahimi-Movaghar, A.; Rahman, M. A.; Rajabpour-
432 Sanati, A.; Rajati, F.; Ramezanzadeh, K.; Ranabhat, C. L.; Rao, P. C.; Rao, S. J.; Rasella,
433 D.; Rastogi, P.; Rathi, P.; Rawaf, D. L.; Rawaf, S.; Rawal, L.; Razo, C.; Redford, S. B.;
434 Reiner, R. C., Jr; Reinig, N.; Reitsma, M. B.; Remuzzi, G.; Renjith, V.; Renzaho, A. M. N.;
435 Resnikoff, S.; Rezaei, N.; Rezai, M. sadegh; Rezapour, A.; Rhinehart, P.-A.; Riahi, S. M.;
436 Ribeiro, A. L. P.; Ribeiro, D. C.; Ribeiro, D.; Rickard, J.; Roberts, N. L. S.; Roberts, S.;
437 Robinson, S. R.; Roever, L.; Rolfe, S.; Ronfani, L.; Roshandel, G.; Roth, G. A.; Rubagotti,
438 E.; Rumisha, S. F.; Sabour, S.; Sachdev, P. S.; Saddik, B.; Sadeghi, E.; Sadeghi, M.;
439 Saeidi, S.; Safi, S.; Safiri, S.; Sagar, R.; Sahebkar, A.; Sahraian, M. A.; Sajadi, S. M.;
440 Salahshoor, M. R.; Salamati, P.; Salehi Zahabi, S.; Salem, H.; Salem, M. R. R.;
441 Salimzadeh, H.; Salomon, J. A.; Salz, I.; Samad, Z.; Samy, A. M.; Sanabria, J.;
442 Santomauro, D. F.; Santos, I. S.; Santos, J. V.; Santric-Milicevic, M. M.; Saraswathy, S. Y.
443 I.; Sarmiento-Suárez, R.; Sarrafzadegan, N.; Sartorius, B.; Sarveazad, A.; Sathian, B.;
444 Sathish, T.; Sattin, D.; Sbarra, A. N.; Schaeffer, L. E.; Schiavolin, S.; Schmidt, M. I.;
445 Schutte, A. E.; Schwebel, D. C.; Schwendicke, F.; Senbeta, A. M.; Senthilkumaran, S.;
446 Sepanlou, S. G.; Shackelford, K. A.; Shadid, J.; Shahabi, S.; Shaheen, A. A.; Shaikh, M.
447 A.; Shalash, A. S.; Shams-Beyranvand, M.; Shamsizadeh, M.; Shannawaz, M.; Sharafi, K.;
448 Sharara, F.; Sheena, B. S.; Sheikhtaheri, A.; Shetty, R. S.; Shibuya, K.; Shiferaw, W. S.;
449 Shigematsu, M.; Shin, J. I.; Shiri, R.; Shirkoohi, R.; Shrimé, M. G.; Shuval, K.; Siabani, S.;

450 Sigfusdottir, I. D.; Sigurvinsdottir, R.; Silva, J. P.; Simpson, K. E.; Singh, A.; Singh, J. A.;
451 Skiadaresi, E.; Skou, S. T.; Skryabin, V. Y.; Sobngwi, E.; Sokhan, A.; Soltani, S.;
452 Sorensen, R. J. D.; Soriano, J. B.; Sorrie, M. B.; Soyiri, I. N.; Sreeramareddy, C. T.;
453 Stanaway, J. D.; Stark, B. A.; Ştefan, S. C.; Stein, C.; Steiner, C.; Steiner, T. J.; Stokes, M.
454 A.; Stovner, L. J.; Stubbs, J. L.; Sudaryanto, A.; Sufiyan, M. B.; Sulo, G.; Sultan, I.; Sykes,
455 B. L.; Sylte, D. O.; Szócska, M.; Tabarés-Seisdedos, R.; Tabb, K. M.; Tadakamadla, S. K.;
456 Taherkhani, A.; Tajdini, M.; Takahashi, K.; Taveira, N.; Teagle, W. L.; Teame, H.; Tehrani-
457 Banihashemi, A.; Teklehaimanot, B. F.; Terrason, S.; Tessema, Z. T.; Thankappan, K. R.;
458 Thomson, A. M.; Tohidinik, H. R.; Tonelli, M.; Topor-Madry, R.; Torre, A. E.; Touvier, M.;
459 Tovani-Palone, M. R. R.; Tran, B. X.; Travillian, R.; Troeger, C. E.; Truelsén, T. C.; Tsai, A.
460 C.; Tsatsakis, A.; Tudor Car, L.; Tyrovolas, S.; Uddin, R.; Ullah, S.; Undurraga, E. A.;
461 Unnikrishnan, B.; Vacante, M.; Vakilian, A.; Valdez, P. R.; Varughese, S.; Vasankari, T. J.;
462 Vasseghian, Y.; Venketasubramanian, N.; Violante, F. S.; Vlassov, V.; Vollset, S. E.;
463 Vongpradith, A.; Vukovic, A.; Vukovic, R.; Waheed, Y.; Walters, M. K.; Wang, J.; Wang, Y.;
464 Wang, Y.-P.; Ward, J. L.; Watson, A.; Wei, J.; Weintraub, R. G.; Weiss, D. J.; Weiss, J.;
465 Westerman, R.; Whisnant, J. L.; Whiteford, H. A.; Wiangkham, T.; Wiens, K. E.; Wijeratne,
466 T.; Wilner, L. B.; Wilson, S.; Wojtyniak, B.; Wolfe, C. D. A.; Wool, E. E.; Wu, A.-M.; Wulf
467 Hanson, S.; Wunrow, H. Y.; Xu, G.; Xu, R.; Yadgir, S.; Yahyazadeh Jabbari, S. H.;
468 Yamagishi, K.; Yaminfirooz, M.; Yano, Y.; Yaya, S.; Yazdi-Feyzabadi, V.; Yearwood, J. A.;
469 Yeheyis, T. Y.; Yeshitila, Y. G.; Yip, P.; Yonemoto, N.; Yoon, S.-J.; Yoosefi Lebni, J.;
470 Younis, M. Z.; Younker, T. P.; Yousefi, Z.; Yousefifard, M.; Yousefinezhadi, T.; Yousuf, A.
471 Y.; Yu, C.; Yusefzadeh, H.; Zahirian Moghadam, T.; Zaki, L.; Zaman, S. B.; Zamani, M.;
472 Zamanian, M.; Zandian, H.; Zangeneh, A.; Zastrozhin, M. S.; Zewdie, K. A.; Zhang, Y.;
473 Zhang, Z.-J.; Zhao, J. T.; Zhao, Y.; Zheng, P.; Zhou, M.; Ziapour, A.; Zimsen, S. R. M.;
474 Naghavi, M.; Murray, C. J. L. Global Burden of 369 Diseases and Injuries in 204 Countries
475 and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study
476 2019. *The Lancet* **2020**, 396 (10258), 1204–1222. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)30925-9)
477 [6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9).
478 (3) Wang, H.; Bhutta, Z. A.; Coates, M. M.; Coggeshall, M.; Dandona, L.; Diallo, K.; Franca, E.
479 B.; Fraser, M.; Fullman, N.; Gething, P. W.; Hay, S. I.; Kinfu, Y.; Kita, M.; Kulikoff, X. R.;
480 Larson, H. J.; Liang, J.; Liang, X.; Lim, S. S.; Lind, M.; Lopez, A. D.; Lozano, R.; Mensah,
481 G. A.; Mikesell, J. B.; Mokdad, A. H.; Mooney, M. D.; Naghavi, M.; Nguyen, G.; Rakovac,
482 I.; Salomon, J. A.; Silpakit, N.; Sligar, A.; Sorensen, R. J. D.; Vos, T.; Zhu, J.; Abajobir, A.
483 A.; Abate, K. H.; Abbas, K. M.; Abd-Allah, F.; Abdulle, A. M.; Abera, S. F.; Aboyans, V.;
484 Abraham, B.; Abubakar, I.; Abu-Raddad, L. J.; Abu-Rmeileh, N. M. E.; Abyu, G. Y.; Achoki,
485 T.; Adebisi, A. O.; Adedeji, I. A.; Adelekan, A. L.; Adou, A. K.; Agarwal, A.; Ajala, O. N.;
486 Akinyemiju, T. F.; Akseer, N.; Alam, K.; Alam, N. K. M.; Alasfoor, D.; Aldridge, R. W.;
487 Alegretti, M. A.; Alemu, Z. A.; Ali, R.; Alkerwi, A.; Alla, F.; Al-Raddadi, R.; Alsharif, U.;
488 Altirkawi, K. A.; Martin, E. A.; Alvis-Guzman, N.; Amare, A. T.; Amberbir, A.; Amegah, A.
489 K.; Ameh, E. A.; Ammar, W.; Amrock, S. M.; Andersen, H. H.; Anderson, G. M.; Antonio, C.
490 A. T.; Ärnlöv, J.; Artaman, A.; Asayesh, H.; Asghar, R. J.; Assadi, R.; Atique, S.; Avokpaho,
491 E. F. G. A.; Awasthi, A.; Quintanilla, B. P. A.; Bacha, U.; Badawi, A.; Balakrishnan, K.;
492 Banerjee, A.; Banigbe, B. F.; Barac, A.; Barber, R. M.; Barker-Collo, S. L.; Bärnighausen,
493 T.; Barrero, L. H.; Bayou, T. A.; Bayou, Y. T.; Bazargan-Hejazi, S.; Beardsley, J.; Bedi, N.;
494 Bekele, T.; Bell, M. L.; Bello, A. K.; Bennett, D. A.; Bensenor, I. M.; Berhane, A.; Bernabé,
495 E.; Betsu, B. D.; Beyene, A. S.; Bhatt, S.; Biadgilign, S.; Bikbov, B.; Birlik, S. M.; Bisanzio,
496 D.; Bjertness, E.; Blore, J. D.; Bourne, R. R. A.; Brainin, M.; Brazinova, A.; Breitborde, N. J.
497 K.; Brown, A.; Buckle, G. C.; Burch, M.; Butt, Z. A.; Campos-Nonato, I. R.; Campuzano, J.
498 C.; Cárdenas, R.; Carpenter, D. O.; Carrero, J. J.; Carter, A.; Casey, D. C.; Castañeda-
499 Orjuela, C. A.; Rivas, J. C.; Castro, R. E.; Catalá-López, F.; Cercy, K.; Chang, H.-Y.;
500 Chang, J.-C.; Chibueze, C. E.; Chisumpa, V. H.; Choi, J.-Y. J.; Chowdhury, R.;

501 Christopher, D. J.; Ciobanu, L. G.; Colquhoun, S. M.; Cooper, C.; Cornaby, L.; Damtew, S.
502 A.; Danawi, H.; Dandona, R.; das Neves, J.; Davis, A. C.; de Jager, P.; De Leo, D.;
503 Degenhardt, L.; Deribe, K.; Deribew, A.; Jarlais, D. C. D.; deVeber, G. A.; Dharmaratne, S.
504 D.; Dhillon, P. K.; Ding, E. L.; Doshi, P. P.; Doyle, K. E.; Duan, L.; Dubey, M.; Ebrahimi, H.;
505 Ellingsen, C. L.; Elyazar, I.; Endries, A. Y.; Ermakov, S. P.; Eshrati, B.; Esteghamati, A.;
506 Faraon, E. J. A.; Farid, T. A.; Farinha, C. S. e S.; Faro, A.; Farvid, M. S.; Farzadfar, F.;
507 Fereshtehnejad, S.-M.; Fernandes, J. C.; Fischer, F.; Fitchett, J. R. A.; Foigt, N.; Franklin,
508 R. C.; Friedman, J.; Fürst, T.; Gambashidze, K.; Gamkrelidze, A.; Ganguly, P.; Gebre, T.;
509 Gebrehiwot, T. T.; Gebremedhin, A. T.; Gebru, A. A.; Geleijnse, J. M.; Gessner, B. D.;
510 Ginawi, I. A. M.; Giref, A. Z.; Gishu, M. D.; Gomez-Dantes, H.; Gona, P.; Goodridge, A.;
511 Gopalani, S. V.; Goto, A.; Gouda, H. N.; Gughani, H. C.; Guo, Y.; Gupta, R.; Gupta, R.;
512 Gupta, V.; Gyawali, B.; Haagsma, J. A.; Hafezi-Nejad, N.; Haile, D.; Hailu, A. D.; Hailu, G.
513 B.; Hamadeh, R. R.; Hamidi, S.; Hancock, J.; Handal, A. J.; Hankey, G. J.; Harb, H. L.;
514 Harikrishnan, S.; Harun, K. M.; Havmoeller, R.; Hay, R. J.; Heredia-Pi, I. B.; Hoek, H. W.;
515 Horino, M.; Horita, N.; Hosgood, H. D.; Hotez, P. J.; Hoy, D. G.; Hsairi, M.; Hu, G.; Huang,
516 C.; Huang, J. J.; Huang, H.; Huiart, L.; Huynh, C.; Iburg, K. M.; Idrisov, B. T.; Innos, K.;
517 Jacobsen, K. H.; Jahanmehr, N.; Javanbakht, M.; Jayatilleke, A. U.; Jee, S. H.; Jeemon,
518 P.; Jha, V.; Jiang, G.; Jiang, Y.; Jibat, T.; Jin, Y.; Jonas, J. B.; Kabir, Z.; Kalkonde, Y.;
519 Kamal, R.; Kan, H.; Kang, G.; Karch, A.; Karema, C. K.; Kasaeian, A.; Kaul, A.; Kawakami,
520 N.; Kayibanda, J. F.; Kazanjan, K.; Keiyoro, P. N.; Kemp, A. H.; Kengne, A. P.; Keren, A.;
521 Kereselidze, M.; Kesavachandran, C. N.; Khader, Y. S.; Khalil, I. A.; Khan, A. R.; Khan, E.
522 A.; Khang, Y.-H.; Khonelidze, I.; Khubchandani, J.; Kim, C.; Kim, D.; Kim, Y. J.; Kisson,
523 N.; Kivipelto, M.; Knibbs, L. D.; Kokubo, Y.; Kosen, S.; Koul, P. A.; Koyanagi, A.; Defo, B.
524 K.; Bicer, B. K.; Kudom, A. A.; Kumar, G. A.; Kutz, M. J.; Kyu, H. H.; Lal, D. K.; Laloo, R.;
525 Lam, H.; Lam, J. O.; Lansingh, V. C.; Larsson, A.; Leigh, J.; Leung, R.; Li, Y.; Li, Y.;
526 Lindsay, M. P.; Liu, P. Y.; Liu, S.; Lloyd, B. K.; Lo, W. D.; Logroscino, G.; Low, N.;
527 Lunevicius, R.; Lyons, R. A.; Ma, S.; Razek, H. M. A. E.; Razek, M. M. A. E.; Mahdavi, M.;
528 Majdan, M.; Majeed, A.; Malekzadeh, R.; Mapoma, C. C.; Marcenes, W.; Martinez-Raga,
529 J.; Marzan, M. B.; Masiye, F.; McGrath, J. J.; Meaney, P. A.; Mehari, A.; Mehndiratta, M.
530 M.; Mekonnen, A. B.; Melaku, Y. A.; Memiah, P.; Memish, Z. A.; Mendoza, W.; Meretoja,
531 A.; Meretoja, T. J.; Mhimbira, F. A.; Miller, T. R.; Mills, E. J.; Mirarefin, M.; Misganaw, A.;
532 Mock, C. N.; Mohammad, K. A.; Mohammadi, A.; Mohammed, S.; Monasta, L.; Hernandez,
533 J. C. M.; Montico, M.; Moore, A. R.; Moradi-Lakeh, M.; Morawska, L.; Mori, R.; Mueller, U.
534 O.; Murphy, G. A. V.; Murthy, S.; Nachege, J. B.; Naheed, A.; Naidoo, K. S.; Naldi, L.;
535 Nand, D.; Nangia, V.; Neupane, S.; Newton, C. R.; Newton, J. N.; Ng, M.; Ngalesoni, F. N.;
536 Nguhiu, P.; Nguyen, Q. L.; Nisar, M. I.; Pete, P. M. N.; Norheim, O. F.; Norman, R. E.;
537 Ogbo, F. A.; Oh, I.-H.; Ojelabi, F. A.; Olivares, P. R.; Olusanya, B. O.; Olusanya, J. O.;
538 Oren, E.; Ota, E.; PA, M.; Park, E.-K.; Park, H.-Y.; Parsaeian, M.; Caicedo, A. J. P.; Patten,
539 S. B.; Pedro, J. M.; Pereira, D. M.; Perico, N.; Pesudovs, K.; Petzold, M.; Phillips, M. R.;
540 Pillay, J. D.; Pishgar, F.; Polinder, S.; Pope, D.; Popova, S.; Pourmalek, F.; Qorbani, M.;
541 Rabiee, R. H. S.; Rafay, A.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M. H. U.;
542 Rahman, S. U.; Rai, R. K.; Raju, M.; Ram, U.; Rana, S. M.; Ranabhat, C. L.; Rao, P.;
543 Refaat, A. H.; Remuzzi, G.; Resnikoff, S.; Reynolds, A.; Rojas-Rueda, D.; Ronfani, L.;
544 Roshandel, G.; Roth, G. A.; Roy, A.; Ruhago, G. M.; Sagar, R.; Saleh, M. M.; Sanabria, J.
545 R.; Sanchez-Niño, M. D.; Santos, I. S.; Santos, J. V.; Sarmiento-Suarez, R.; Sartorius, B.;
546 Satpathy, M.; Savic, M.; Sawhney, M.; Schneider, I. J. C.; Schöttker, B.; Schwebel, D. C.;
547 Seedat, S.; Sepanlou, S. G.; Servan-Mori, E. E.; Setegn, T.; Shahrzad, S.; Shaikh, M. A.;
548 Shakh-Nazarova, M.; Sharma, R.; She, J.; Sheikhbahaei, S.; Shen, J.; Sheth, K. N.;
549 Shibuya, K.; Shin, H. H.; Shin, M.-J.; Shiri, R.; Shui, I.; Sigfusdottir, I. D.; Silva, D. A. S.;
550 Silverberg, J.; Simard, E. P.; Sindi, S.; Singh, A.; Singh, J. A.; Singh, O. P.; Singh, P. K.;
551 Singh, V.; Soriano, J. B.; Soshnikov, S.; Sposato, L. A.; Sreeramareddy, C. T.;

- 552 Stathopoulou, V.; Steel, N.; Stroumpoulis, K.; Sturua, L.; Sunguya, B. F.; Swaminathan, S.;
553 Sykes, B. L.; Szoeki, C. E. I.; Tabarés-Seisdedos, R.; Tavakkoli, M.; Taye, B.; Tedla, B.
554 A.; Tefera, W. M.; Tekle, T.; Shifa, G. T.; Terkawi, A. S.; Tesfay, F. H.; Tessema, G. A.;
555 Thapa, K.; Thomson, A. J.; Thorne-Lyman, A. L.; Tobe-Gai, R.; Tonelli, M.; Topor-Madry,
556 R.; Topouzis, F.; Tran, B. X.; Troeger, C.; Truelsen, T.; Dimbuene, Z. T.; Tura, A. K.;
557 Tyrovolas, S.; Ukwaja, K. N.; Uneke, C. J.; Uthman, O. A.; Vaezghasemi, M.; Vasankari,
558 T.; Vasconcelos, A. M. N.; Venketasubramanian, N.; Verma, R. K.; Violante, F. S.;
559 Vladimirov, S. K.; Vlassov, V. V.; Vollset, S. E.; Wang, L.; Wang, Y.; Weichenthal, S.;
560 Weiderpass, E.; Weintraub, R. G.; Weiss, D. J.; Werdecker, A.; Westerman, R.;
561 Widdowson, M.-A.; Wijeratne, T.; Williams, T. N.; Wiysonge, C. S.; Wolfe, C. D. A.; Wolfe,
562 I.; Won, S.; Wubshet, M.; Xiao, Q.; Xu, G.; Yadav, A. K.; Yakob, B.; Yano, Y.; Yaseri, M.;
563 Ye, P.; Yebayo, H. G.; Yip, P.; Yonemoto, N.; Yoon, S.-J.; Younis, M. Z.; Yu, C.; Zaidi, Z.;
564 Zaki, M. E. S.; Zeeb, H.; Zhang, H.; Zhao, Y.; Zheng, Y.; Zhou, M.; Zodpey, S.; Murray, C.
565 J. L. Global, Regional, National, and Selected Subnational Levels of Stillbirths, Neonatal,
566 Infant, and under-5 Mortality, 1980–2015: A Systematic Analysis for the Global Burden of
567 Disease Study 2015. *The Lancet* **2016**, 388 (10053), 1725–1774.
568 [https://doi.org/10.1016/S0140-6736\(16\)31575-6](https://doi.org/10.1016/S0140-6736(16)31575-6).
- 569 (4) Killerby, M. E.; Biggs, H. M.; Haynes, A.; Dahl, R. M.; Mustaquim, D.; Gerber, S. I.;
570 Watson, J. T. Human Coronavirus Circulation in the United States 2014–2017. *Journal of*
571 *Clinical Virology* **2018**, 101, 52–56. <https://doi.org/10.1016/j.jcv.2018.01.019>.
- 572 (5) Olsen, S. J.; Winn, A. K.; Budd, A. P.; Prill, M. M.; Steel, J.; Midgley, C. M.; Kniss, K.;
573 Burns, E.; Rowe, T.; Foust, A.; Jasso, G.; Merced-Morales, A.; Davis, C. T.; Jang, Y.;
574 Jones, J.; Daly, P.; Gubareva, L.; Barnes, J.; Kondor, R.; Sessions, W.; Smith, C.;
575 Wentworth, D. E.; Garg, S.; Havers, F. P.; Fry, A. M.; Hall, A. J.; Brammer, L.; Silk, B. J.
576 Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic
577 - United States, 2020–2021. *MMWR Morb Mortal Wkly Rep* **2021**, 70 (29), 1013–1019.
578 <https://doi.org/10.15585/mmwr.mm7029a1>.
- 579 (6) Chow, E. J.; Uyeki, T. M.; Chu, H. Y. The Effects of the COVID-19 Pandemic on
580 Community Respiratory Virus Activity. *Nature Reviews Microbiology* **2023**, 21 (3), 195–
581 210. <https://doi.org/10.1038/s41579-022-00807-9>.
- 582 (7) Boehm, A. B.; Hughes, B.; Duong, D.; Chan-Herur, V.; Buchman, A.; Wolfe, M. K.; White,
583 B. J. Wastewater Concentrations of Human Influenza, Metapneumovirus, Parainfluenza,
584 Respiratory Syncytial Virus, Rhinovirus, and Seasonal Coronavirus Nucleic-Acids during
585 the COVID-19 Pandemic: A Surveillance Study. *The Lancet Microbe* **2023**.
586 [https://doi.org/10.1016/S2666-5247\(22\)00386-X](https://doi.org/10.1016/S2666-5247(22)00386-X).
- 587 (8) Hamid, S.; Winn, A.; Parikh, R.; Jones, J.; McMorro, M.; Prill, M.; Silk, B. J.; Scobie, H.
588 M.; Hall, A. J. Seasonality of Respiratory Syncytial Virus — United States, 2017–2023.
589 *MMWR Morb Mortal Wkly Rep* **2023**, 72, 355–361.
590 <http://dx.doi.org/10.15585/mmwr.mm7214a1>.
- 591 (9) Furlow, B. Triple-Demic Overwhelms Paediatric Units in US Hospitals. *The Lancet Child &*
592 *Adolescent Health* **2023**, 7 (2), 86. [https://doi.org/10.1016/S2352-4642\(22\)00372-8](https://doi.org/10.1016/S2352-4642(22)00372-8).
- 593 (10) Weixel, N. 'Tripledemic' Infected Nearly 40 Percent of Households, Survey Finds. *The Hill*.
594 February 7, 2023. [https://thehill.com/policy/healthcare/3846161-tripledemic-infected-](https://thehill.com/policy/healthcare/3846161-tripledemic-infected-nearly-40-percent-of-households-survey-finds/)
595 [nearly-40-percent-of-households-survey-finds/](https://thehill.com/policy/healthcare/3846161-tripledemic-infected-nearly-40-percent-of-households-survey-finds/) (accessed 2023-05-22).
- 596 (11) Chow, Y. P.; Chin, B. H. Z.; Loo, J. M.; Moorthy, L. R.; Jairaman, J.; Tan, L. H.; Tay, W. W.
597 Y. Clinical and Epidemiological Characteristics of Patients Seeking COVID-19 Testing in a
598 Private Centre in Malaysia: Is There a Role for Private Healthcare in Battling the
599 Outbreak? *PLOS ONE* **2021**, 16 (10), e0258671.
600 <https://doi.org/10.1371/journal.pone.0258671>.
- 601 (12) Radar, B.; Gertz, A.; Iuliano, A. D.; Gilmer, M.; Wronski, L.; Astley, C. M.; Sewalk, K.;
602 Varrelman, T.; Cohen, J.; Parikh, R.; Reese, H. E.; Reed, C.; Brownstein, J. S. Use of At-

- 603 Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022. *MMWR Morb*
604 *Mortal Wkly Rep* **2022**, *71*, 489–494. <http://dx.doi.org/10.15585/mmwr.mm7113e1>.
- 605 (13) McElfish, P. A.; Purvis, R.; James, L. P.; Willis, D. E.; Andersen, J. A. Perceived Barriers to
606 COVID-19 Testing. *International Journal of Environmental Research and Public Health*
607 **2021**, *18* (5). <https://doi.org/10.3390/ijerph18052278>.
- 608 (14) Jajosky, R. A.; Groseclose, S. L. Evaluation of Reporting Timeliness of Public Health
609 Surveillance Systems for Infectious Diseases. *BMC Public Health* **2004**, *4* (1), 29.
610 <https://doi.org/10.1186/1471-2458-4-29>.
- 611 (15) Simonsen, L.; Gog, J. R.; Olson, D.; Viboud, C. Infectious Disease Surveillance in the Big
612 Data Era: Towards Faster and Locally Relevant Systems. *The Journal of Infectious*
613 *Diseases* **2016**, *214* (suppl_4), S380–S385. <https://doi.org/10.1093/infdis/jiw376>.
- 614 (16) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet,
615 M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput
616 Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned
617 Treatment Works in Northern California Shows Strong Association with COVID-19
618 Incidence. *mSystems* **2021**, *6* (5), e00829-21. <https://doi.org/10.1128/mSystems.00829-21>.
- 619 (17) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical
620 Processing of Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. *protocols.io*
621 **2021**.
- 622 (18) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. High Throughput RNA Extraction
623 and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2
624 RNA. *protocols.io* **2021**.
- 625 (19) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull,
626 A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.;
627 Wigginton, K. R.; Wolfe, M. K.; Kohn, T.; Ort, C.; Stadler, T.; Julian, T. R. Wastewater-
628 Based Estimation of the Effective Reproductive Number of SARS-CoV-2. *Environmental*
629 *Health Perspectives* **2022**, *130* (5), 057011–1.
- 630 (20) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper Mild Mottle Virus: A
631 Plant Pathogen with a Greater Purpose in (Waste)Water Treatment Development and
632 Public Health Management. *Water Research* **2018**, *144*, 1–12.
633 <https://doi.org/10.1016/j.watres.2018.06.066>.
- 634 (21) Simpson, A.; Topol, A.; White, B.; Wolfe, M. K.; Wigginton, K.; Boehm, A. B. Effect of
635 Storage Conditions on SARS-CoV-2 RNA Quantification in Wastewater Solids. *PeerJ*
636 **2021**, *9*, e11933. <https://doi.org/10.7717/peerj.11933>.
- 637 (22) California Influenza Surveillance Program. *Influenza and Other Respiratory Viruses*
638 *Weekly Report*; 2023.
639 [https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunizat](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/Week2021-2245_FINALReport.pdf)
640 [ion/Week2021-2245_FINALReport.pdf](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/Week2021-2245_FINALReport.pdf) (accessed 2023-06-08).
- 641 (23) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong;
642 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations
643 in Wastewater Solids from Central and Coastal California, USA. *Scientific Data* **2023**,
644 Accepted.
- 645 (24) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T.
646 The Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and
647 DPCR Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.* **2021**,
648 *55* (15), 10210–10223. <https://doi.org/10.1021/acs.est.1c01767>.
- 649 (25) van den Hoogen, B. G.; de Jong, J. C.; Groen, J.; Kuiken, T.; de Groot, R.; Fouchier, R. A.;
650 Osterhaus, A. D. A Newly Discovered Human Pneumovirus Isolated from Young Children
651 with Respiratory Tract Disease. *Nat Med* **2001**, *7* (6), 719–724.
652 <https://doi.org/10.1038/89098>.
- 653 (26) VAN DEN HOOGEN, B. G.; OSTERHAUS, D. M. E.; FOUCHIER, R. A. M. Clinical Impact


- 654 and Diagnosis of Human Metapneumovirus Infection. *The Pediatric Infectious Disease*
655 *Journal* **2004**, 23 (1).
- 656 (27) Edwards, K. M.; Zhu, Y.; Griffin, M. R.; Weinberg, G. A.; Hall, C. B.; Szilagyi, P. G.; Staat,
657 M. A.; Iwane, M.; Prill, M. M.; Williams, J. V. Burden of Human Metapneumovirus Infection
658 in Young Children. *N Engl J Med* **2013**, 368 (7), 633–643.
659 <https://doi.org/10.1056/NEJMoa1204630>.
- 660 (28) Wei, C.-J.; Crank, M. C.; Shiver, J.; Graham, B. S.; Mascola, J. R.; Nabel, G. J. Next-
661 Generation Influenza Vaccines: Opportunities and Challenges. *Nature Reviews Drug*
662 *Discovery* **2020**, 19 (4), 239–252. <https://doi.org/10.1038/s41573-019-0056-x>.
- 663 (29) Mejias, A.; Rodríguez-Fernández, R.; Oliva, S.; Peeples, M. E.; Ramilo, O. The Journey to
664 a Respiratory Syncytial Virus Vaccine. *Annals of Allergy, Asthma & Immunology* **2020**, 125
665 (1), 36–46. <https://doi.org/10.1016/j.anai.2020.03.017>.
- 666 (30) US FDA. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine.
667 [https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine)
668 [syncytial-virus-rsv-vaccine](https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine) (accessed 2023-06-08).
- 669 (31) Center for Disease Control. Human metapneumovirus. [https://www.cdc.gov/ncird/human-](https://www.cdc.gov/ncird/human-metapneumovirus.html)
670 [metapneumovirus.html](https://www.cdc.gov/ncird/human-metapneumovirus.html) (accessed 2023-05-23).
- 671 (32) Li, Y.; Reeves, R. M.; Wang, X.; Bassat, Q.; Brooks, W. A.; Cohen, C.; Moore, D. P.;
672 Nunes, M.; Rath, B.; Campbell, H.; Nair, H.; Acacio, S.; Alonso, W. J.; Antonio, M.; Ayora
673 Talavera, G.; Badarch, D.; Baillie, V. L.; Barrera-Badillo, G.; Bigogo, G.; Broor, S.; Bruden,
674 D.; Buchy, P.; Byass, P.; Chipeta, J.; Clara, W.; Dang, D.-A.; de Freitas Lázaro Emediato,
675 C. C.; de Jong, M.; Díaz-Quinonez, J. A.; Do, L. A. H.; Fasce, R. A.; Feng, L.; Ferson, M.
676 J.; Gentile, A.; Gessner, B. D.; Goswami, D.; Goyet, S.; Grijalva, C. G.; Halasa, N.;
677 Hellferscee, O.; Hessong, D.; Homaira, N.; Jara, J.; Kahn, K.; Khuri-Bulos, N.; Kotloff, K.
678 L.; Lanata, C. F.; Lopez, O.; Lopez Bolaños, M. R.; Lucero, M. G.; Lucion, F.; Lupisan, S.
679 P.; Madhi, S. A.; Mekgoe, O.; Moraleda, C.; Moyes, J.; Mulholland, K.; Munywoki, P. K.;
680 Naby, F.; Nguyen, T. H.; Nicol, M. P.; Nokes, D. J.; Noyola, D. E.; Onozuka, D.; Palani, N.;
681 Poovorawan, Y.; Rahman, M.; Ramaekers, K.; Romero, C.; Schlaudecker, E. P.;
682 Schweiger, B.; Seidenberg, P.; Simoes, E. A. F.; Singleton, R.; Sistla, S.; Sturm-Ramirez,
683 K.; Suntronwong, N.; Sutanto, A.; Tapia, M. D.; Thamthitawat, S.; Thongpan, I.;
684 Tillekeratne, G.; Tinoco, Y. O.; Treurnicht, F. K.; Turner, C.; Turner, P.; van Doorn, R.; Van
685 Ranst, M.; Visseaux, B.; Waicharoen, S.; Wang, J.; Yoshida, L.-M.; Zar, H. J. Global
686 Patterns in Monthly Activity of Influenza Virus, Respiratory Syncytial Virus, Parainfluenza
687 Virus, and Metapneumovirus: A Systematic Analysis. *The Lancet Global Health* **2019**, 7
688 (8), e1031–e1045. [https://doi.org/10.1016/S2214-109X\(19\)30264-5](https://doi.org/10.1016/S2214-109X(19)30264-5).
- 689 (33) Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D. Divergence of Wastewater
690 SARS-CoV-2 and Reported Laboratory-Confirmed COVID-19 Incident Case Data
691 Coincident with Wide-Spread Availability of at-Home COVID-19 Antigen Tests. *PeerJ*
692 **2023**, Accepted.
- 693 (34) Wolfe, M. K.; Yu, A. T.; Duong, D.; Rane, M. S.; Hughes, B.; Chan-Herur, V.; Donnelly, M.;
694 Chai, S.; White, B. J.; Vugia, D. J.; Boehm, A. B. Use of Wastewater for Mpox Outbreak
695 Surveillance in California. *N Engl J Med* **2023**. <https://doi.org/10.1056/NEJMc2213882>.
- 696
697
698
699
700
701
702
703

704
705
706
707
708
709

Table 1. Date of onset and offset, as well as peak of wastewater events for each human viral target measured in wastewater solids for each of 8 POTWs. A “?” indicates that the offset had not yet occurred during the study period. Dates for two events are provided if two wastewater events were identified. SC2 is SARS-CoV-2, only the peak is provided for SC2.

POTW	HMPV		IAV		RSV		SC2
	onset/offset	peak	onset/offset	peak	onset/offset	peak	peak
Gil	3 Dec - ?	3 Jan	13 Nov - 25 Jan	30 Nov	24 Oct - 20 Mar	30 Nov	1 Dec
SJ	30 Oct - ?	22 March	14 July - 23 July 8 Nov - 3 Mar	30 Nov	17 Sept - 18 April	20 Dec	1 Dec
PA	1 Nov - ?	26 Nov	14 July - 21 Sept 11 Nov - 13 Feb	26 Nov	11 Oct - 2 April	25 Nov	30 Nov
SVCW	12 Nov - ?	6 Dec	4 Nov - 24 Feb	9 Dec	23 Sept - 25 April	13 Dec	4 Mar
SE	1 Sept - 24 Sept 13 Oct - ?	1 April	26 Oct - 25 Feb	8 Dec	6 Oct - 25 Mar	29 Nov	5 Jan
Ocean	6 Aug - ?	30 March	18 Nov - 22 Feb	13 Dec	23 Sept - 17 April	4 Dec	16 Mar
SAC	10 Nov - ?	13 March	4 Nov - 30 Jan	24 Nov	19 Oct - 27 Mar	14 Dec	7 Dec
Sun	4 Nov - ?	2 March	10 Nov - 1 Mar	2 Dec	26 Sept - 29 April	3 Dec	9 Feb

710



711
712 Figure 1. Time series of concentrations of SARS-CoV-2, RSV, IAV, and HMPV normalized by
713 PMMoV in wastewater solids at eight POTWs between 7/1/22 and 5/7/23; the ratio is unitless.
714 Raw data are shown as filled circles, lines are 5-d trimmed averages. Note the difference in
715 scale between the SARS-CoV-2 (upper left axis of each panel) and the other viruses (lower left
716 axis of each panel). The acronym for each POTW is provided in the upper left corner.
717

1 Supporting information for

2

3 Community occurrence of metapneumovirus, influenza A, and respiratory syncytial virus (RSV)
4 inferred from wastewater solids during the winter 2022-2023 tripledemic

5

6 **Authors**

7 Alexandria B. Boehm^{1*}, Marlene K. Wolfe², Bradley White³, Bridgette Hughes³, Dorothea Duong³,
8 Amanda Bidwell¹

9

10

11 **Affiliations**

12 1. Department of Civil & Environmental Engineering, School of Engineering and Doerr School of
13 Sustainability, Stanford University, Stanford, CA, USA

14 2. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
15 University, Atlanta, GA, USA

16 3. Verily Life Sciences, South San Francisco, CA, USA

17

18

19

20 *corresponding author: Alexandria Boehm (aboehm@stanford.edu)

21

22

23

24 **Number of pages: 13**

25 **Number of Tables: 3**

26 **Number of Figures: 6**

27

28

29

30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74

Additional details of sample collection. At seven of the eight POTWs, settled solids were collected from the primary clarifier. Settled solids samples were grab samples except for at SJ where staff collected a 24-h composite sample¹. At Gil, solids were settled from a 24-h composite influent sample using standard method 160.5².

Additional details of sample processing and nucleic-acid extraction. Briefly, solids were dewatered by centrifugation, and an aliquot of dewatered solids was dried to determine its dry weight, and another aliquot was resuspended in the bovine coronavirus (BCoV)-spiked DNA/RNA shield (Zymo Research) at a concentration of 75 mg/ml. Bovine coronavirus (BCoV) was used as a positive recovery control. This concentration of solids was chosen as previous work titrated solutions with various concentrations of solids to identify a concentration that minimized inhibition while maintaining sensitivity of the assays^{3,4}. The suspension was homogenized, and then centrifuged. The supernatant was subjected to nucleic acid extraction.

Additional details of digital droplet RT-PCR. Digital droplet PCR was performed on 20- μ l samples from a 22- μ l reaction volume, prepared using 5.5- μ l template, mixed with 5.5 μ l of One-Step RT-ddPCR Advanced kit for Probes (catalog no. 1863021; Bio-Rad), 2.2 μ l reverse transcriptase, 1.1 μ l dithiothreitol (DTT), and primers and probes at a final concentration of 900 nM and 250 nM, respectively. Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad). PCR was performed using Mastercycler Pro with the following protocol: reverse transcription at 50°C for 60 min, enzyme activation at 95°C for 5 min, 40 cycles with 1 cycle consisting of denaturation at 95°C for 30 s and annealing and extension at either 59°C or 61°C (for human viruses) or 56°C (for PMMoV/BCoV duplex assay) for 30 s, enzyme deactivation at 98°C for 10 min, and then an indefinite hold at 4°C. The ramp rate for temperature changes was set at 2°C/s, and the final hold at 4°C was performed for a minimum of 30 min to allow the droplets to stabilize.

All samples were processed for HMPV in multiplex as described in the Data Descriptor by Boehm et al.⁴. For the remaining human viral assay, samples collected between 7/1/22 and 3/11/23, were processed in multiplex as described in the Data Descriptor by Boehm et al.⁴ Thereafter, for all samples collected between 3/12/23 and 5/7/23 (month/day/year format), assays for SARS-CoV-2 N gene (FAM), RSV (Cy5), and IAV (Cy5.5) were multiplexed using the probe mixing method; the multiplex assay also contained assays for influenza B and norovirus GII for which results are not presented herein. This assay was run at an annealing temperature of 61°C. BCoV and PMMoV were run in a duplex assay.

Each sample was run in 10 replicate wells. On each 96 well plate, extraction-negative controls were run in 3 wells, and extraction-positive controls in 1 well. PCR-positive controls of SARS-CoV-2, IAV, RSV, HMPV, BCoV, and PMMoV were run in 1 well, and no-template controls (NTC) were run in 3 wells. Positive controls consisted of BCoV and PMMoV gene block controls and the same human virus controls described in the main text as positive extraction controls. Results from replicate wells were merged for analysis.

75
76 Droplets were analyzed using the QX200 or QX600 Droplet Reader (Bio-Rad). Each sample
77 was run in 10 replicate wells on 96 well plates that also contained positive and negative
78 extraction and PCR controls (see SI). Thresholding was done using QuantaSoft Analysis Pro
79 software (Bio-Rad, version 1.0.596). In order for a sample to be recorded as positive, it had to
80 have at least three positive droplets. Three positive droplets corresponds to a concentration
81 between ~500 and 1000 copies (cp)/g dry weight; the range in values is a result of the range in
82 the equivalent mass of dry solids added to the wells. Any plates for which negative controls
83 were positive or positive controls were negative were discarded and the samples re-processed
84 and rerun.

85
86 **IAV subtype assay design and testing.** To design the primers and probes, influenza A
87 genome sequences were downloaded from NCBI in January 2023 and aligned to identify
88 conserved regions in the specified regions of the genome. Then primers and probes targeting
89 those conserved regions were developed in silico using Primer3Plus (<https://primer3plus.com/>)
90 (Table S2).

91
92 Primers and probes were then screened for specificity in silico, and in vitro against other
93 respiratory and enteric viruses. including adenoviruses, coronaviruses, metapneumovirus,
94 parainfluenza, RSV, coxsackievirus, echovirus, parechovirus (NATrol Respiratory Verification
95 Panel NATRVP2.1-BIO and NATrol EV Panel NATEVP-C viral panels, Zeptometrix, Buffalo,
96 NY), as well as synthetic genomic RNA from influenza A H1N1 and influenza A H3N2 (Twist
97 Bioscience, South San Francisco, CA).

98
99 **Measuring IAV subtype markers in wastewater solids.** RNA extracts from the two POTWs
100 (SJ and Ocean) were stored at -80°C for 1-5 months. RNA was subjected to a single freeze-
101 thaw and used as template undiluted in digital droplet PCR using the same methods outlined
102 above. Assays were run in multiplex using the probe mixing approach. H1 and N1 were
103 multiplexed in the HEX and Cy5.5 channels, respectively. H3, N2, and IAV were multiplexed in
104 the HEX, FAM/HEX, and ROX channels. Ten replicates were run for each sample, for each
105 sample with the same number of positive and negative extraction and PCR controls per plate as
106 described for the prospective measurements described in the main text. Positive controls
107 consisted of synthetic genomic RNA from influenza H1N1 and H3N2 (Twist). Results are
108 reported as copies per gram dry weight.

109
110 **Correlations between wastewater and clinical positivity rates.** IAV in wastewater solids
111 was significantly associated with state-aggregated weekly clinical specimen influenza positivity
112 rates at all POTWs (tau between 0.54 and 0.73, all $p < 10^{-6}$) except for SVCW and Sun where the
113 association was not statistically significant. Weekly median normalized RSV in wastewater
114 solids was significantly associated with state-aggregated weekly clinical specimen RSV

115 positivity rates at all plants (tau between 0.59 and 0.67, all $p < 10^{-7}$). Weekly median normalized
116 HMPV in wastewater solids was significantly associated with state-aggregated weekly clinical
117 specimen HMPV positivity rates at all plants (tau between 0.52 and 0.72, $p < 10^{-6}$). Daily
118 normalized SARS-CoV-2 was positively associated with daily state-aggregated COVID-19
119 positivity rates (tau between 0.27 and 0.48, all $p < 10^{-11}$), as has been shown extensively in
120 previous work.^{1,5}

121


122 **References**

123

- 124 (1) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet,
125 M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput
126 Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned
127 Treatment Works in Northern California Shows Strong Association with COVID-19
128 Incidence. *mSystems* **2021**, 6 (5), e00829-21. <https://doi.org/10.1128/mSystems.00829-21>.
- 129 (2) AWWA. *Standard Methods for the Examination of Water and Wastewater*, 21st ed.; Eaton,
130 A. D., Clesceri, L. S., Rice, E. W., Greenberg, A. E., Series Eds.; American Public Health
131 Association, American Water Works Association, Water Environment Federation: Baltimore,
132 2005.
- 133 (3) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull,
134 A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.;
135 Wigginton, K. R.; Wolfe, M. K.; Kohn, T.; Ort, C.; Stadler, T.; Julian, T. R. Wastewater-
136 Based Estimation of the Effective Reproductive Number of SARS-CoV-2. *Environmental*
137 *Health Perspectives* **2022**, 130 (5), 057011–1.
- 138 (4) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong;
139 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations
140 in Wastewater Solids from Central and Coastal California, USA. *Scientific Data* **2023**,
141 Accepted.
- 142 (5) Duvall, C.; Wu, F.; McElroy, K. A.; Imakaev, M.; Endo, N.; Xiao, A.; Zhang, J.; Floyd-
143 O'Sullivan, R.; Powell, M. M.; Mendola, S.; Wilson, S. T.; Cruz, F.; Melman, T.;
144 Sathyanarayana, C. L.; Olesen, S. W.; Erickson, T. B.; Ghaeli, N.; Chai, P.; Alm, E. J.;
145 Matus, M. Nationwide Trends in COVID-19 Cases and SARS-CoV-2 RNA Wastewater
146 Concentrations in the United States. *ACS EST Water* **2022**, 2 (11), 1899–1909.
147 <https://doi.org/10.1021/acsestwater.1c00434>.
- 148 (6) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T. The
149 Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and DPCR
150 Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.* **2021**, 55 (15),
151 10210–10223. <https://doi.org/10.1021/acs.est.1c01767>.

152

153
154
155



156
157
158

Figure S1. Map of sewersheds participating in the study.

159

Environmental Microbiology Minimum Information Checklist

Study Description

Study: SCAN
Date: March 2023
Completed by: Alexandria Boehm

Environmental Sampling	Sample Treatment	Sample Reduction	Nucleic Acid Extraction	Reverse Transcription	PCR Detection	Analysis
Described in methods section	<input type="checkbox"/> Performed No sample treatment performed	<input checked="" type="checkbox"/> Performed Centrifugation was used, as described in the methods	Methods provided in the Data Descriptor.	<input checked="" type="checkbox"/> Performed One Step RT-PCR	<input type="checkbox"/> qPCR <input checked="" type="checkbox"/> dPCR All methods provided including the dMEI checklist	No formal analysis was done in this project

Control Checklist

	Environmental Sampling	Sample Treatment	Sample Reduction	Nucleic Acid Extraction	Reverse Transcription	PCR Detection	
Step performed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Step has control info	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Negative Controls
# control replicates	0	0	0	3	3	3	
Control result reported	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Data handling reported	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Control introduced	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Positive Controls
Internal/External	N/A	N/A	Internal	External	External	External	
Independent/Parallel	N/A	N/A	Parallel	Independent	Independent	Independent	
Step has control info	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
# control replicates	0	0	10	1	1	1	
Control result reported	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Data Handling reported	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	

Process Checklist

Environmental Sampling

- Sampling Procedure
- Number of samples
- Sample amount, mean, range
- Sampling locations, dates, times

Sample Reduction

- Performed
- Reduction procedure
- Reagents
- Concentration Factor

qPCR or dPCR

- Target gene name, amplicon length
- Thermocycling temperatures and times
- Master mix: composition, vendors, concentrations
- Additives: vendors, concentrations
- Template amount added, pre-treatment (if any)
- Primers: sequences, concentrations, vendors, references
- Amplicon confirmation method (probe, melt curve, etc)
- Probe sequence, concentration, vendor, reference
- Instrumentation
- Equivalent volume of sample analyzed by PCR
- Inhibition assessment procedure
- Inhibition control description (if used)
- Number samples tested and found inhibited

Sample Treatment

- Performed
- Treatment procedure
- Reagents

Nucleic Acid Extraction

- Extraction procedure
- Amount extracted, amount obtained
- Extract storage conditions

Reverse Transcription

- Performed
- One or two step
- cDNA storage conditions (if two step)
- Reaction temperatures and times
- Reaction reagents and concentrations
- Priming method
- Reaction volume, added template amount
- Inhibition assessment procedure
- Inhibition control description (if used)
- Number samples tested and found inhibited

Analysis – dPCR

- Threshold settings
- Technical replicates, number, well merging
- Partitions measured, number, mean, variance
- Partition volume
- Target copies per partition, mean, variance
- Program used for dPCR analysis
- Explanation of control results, example plots

Analysis – qPCR

- Method for handling failed negative controls
- Technical replicates, number, calculations
- Calibration standards: description and source
- Method of quantifying standards
- Calibration curve slope
- Calibration curve R2
- Lowest standard measured or 95% LOD
- Cq value determination method

160


161

162 Figure S2. EMMI checklist⁶. Details of the partition numbers and volume, and copy numbers per
 163 partition are reported in a Data Descriptor⁴.


164

S6


165
166
167




168
169 Figure S3. The distribution of between POTW Kendall's tau values for each human viral target.
170 There are 28 tau values for each virus (each combination of 2 POTW among the 8), and those
171 are shown as gray circles. The box and whisker plot provides a visualization of the distribution.
172 The whiskers extend from the 9th to 91st percentiles. The bottom and top of the box represent
173 the 25th and 75th percentiles, the line through the middle of the box represents the median.
174
175
176
177
178



179
180 Figure S4. The distribution of within POTW Kendall's tau values for different human viral targets
181 comparisons (bottom axis). There are 8 tau values for each virus combination (1 for each
182 POTW), and those are shown as gray circles. The box and whisker plot provides a visualization
183 of the distribution. The whiskers extend from the 9th to 91st percentiles. The bottom and top of
184 the box represent the 25th and 75th percentiles, the line through the middle of the box
185 represents the median. SC2 is SARS-CoV-2. All tau values are shown, even those that are not
186 significantly different from 0.
187



188
189
190 Figure S5. Positivity rates for influenza A (IAV), RSV, human metapneumovirus (HMPV) and
191 SARS-CoV-2 in clinical specimens aggregated across the state of California. Data are reported
192 weekly for IAV, RSV, and HMPV, and daily for SARS-CoV-2.
193
194
195



196
197
198
199
200
201
202
203
204
205
206
207
208
209
210

Figure S6. Panel A. Concentrations of IAV, N1, N2, H1, and H3 in copies per gram dry weight in archived samples from SJ POTW. Panel B. Distributions of the ratio of each IAV subtype marker and IAV measured in the archived samples. Only non-zero ratios are included, aside from N1 for which all values were 0. The whiskers extend from the 9th to 91st percentiles. The bottom and top of the box represent the 25th and 75th percentiles, the line through the middle of the box represents the median.

211
212
213

Table S1. Primers and probes of previously published assays.

Target	Primer/Probe	Sequence
SARS-CoV-2 N Gene	Forward	CATTACGTTTGGTGGACCCT
	Reverse	CCTTGCCATGTTGAGTGAGA
	Probe	CGCGATCAAAACAACGTCGG
BCoV	Forward	CTGGAAGTTGGTGGAGTT
	Reverse	ATTATCGGCCTAACATACATC
	Probe	CCTTCATATCTATACACATCAAGTTGTT
PMMoV	Forward	GAGTGGTTTGACCTTAACGTTTGA
	Reverse	TTGTCGGTTGCAATGCAAGT
	Probe	CCTACCGAAGCAAATG
Influenza A	Forward	CAAGACCAATCYTGTCACCTCTGAC
	Reverse	GCATTYTGGACAAAVCGTCTACG
	Probe	TGCAGTCCTCGCTCACTGGGCACG
RSV	Forward	CTCCAGAATAYAGGCATGAYTCTCC
	Reverse	GCYCTYCTAATYACWGCTGTAAGAC
	Probe	TAACCAAATTAGCAGCAGGAGATAGATCAG
HMPV	Forward	ACTTTATTGGAGAAGGAGCAGG
	Reverse	GGGTAATGRTGATCAAGRTCA
	Probe	AYTGGATGGCMAGAACAGCA

214
215

216

217

218 Table S2. Parameters used with primer design software.

- 219 ● Product size ranges: 60-275
- 220 ● Primer size: min 15, opt 20, max 36
- 221 ● Primer melting temperature: min 50°C, optimal 60°C, max 65°C - GC% content: min
- 222 40%, optimal 50%, high 60%
- 223 ● concentration of divalent cations = 3.8 mM
- 224 ● concentration of dNTPs needs to be 0.8 mM
- 225 ● Internal Oligo: size min 15, optimal 20, max 30
- 226 ● Internal Oligo: Melting temp min 62°C, optimal 63°C, max 70°C
- 227 ● Internal Oligo: GC% min 30%, optimal 50%, max 80%

228

229

230

231 Table S3. Novel influenza A (IAV) H1, H3, N1, and N2 assays developed in this study. Forward and.
 232 reverse primers and probes are provided. Assays were run at 59°C annealing temperatures.

H1 (IAV)	Forward	GTGAATCACTCTCCACAGCA
	Reverse	TGATTRGGCCATGAACTTGT
	Probe	TGGAACGTGTTACCCAGGAGA
H3 (IAV)	Forward	GAGRTCAGATGCACCCATTG
	Reverse	TCTGGTACATTYCGCATCCC
	Probe	TGCATCACTCCAAATGGAAGCA
N1 (IAV)	Forward	TCYCCCTTGGAAATGCAGAAC
	Reverse	ACCAAGCGACTGACTCAAAT
	Probe	AGGAGYCCATATCGAACCT
N2 (IAV)	Forward	GTGTTATCAATTTGCCCTTGG
	Reverse	GGTCCGATAAGGGGTCCTAT
	Probe	CAGGGAACAACACTAAACAACGTG

233